YIH
CARM

Y-Intercept (HK)’s Carisma Therapeutics CARM Stock Holding History

Y-Intercept (HK)’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-75,501
Closed -$115K – 1344
2024
Q2 		$115K Buy
+75,501
New +$113K 0.01% 1247
2022
Q3 		– Sell
-1,504
Closed -$24K – 982
2022
Q2 		$24K Buy
+1,504
New +$17.2K ﹤0.01% 782

Other funds holding CARM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TOTUOP
Trustees of The University of Pennsylvania Philaldelphia, Pennsylvania $297M AUM
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Y-Intercept (HK)'s CARM Position: Q3 2024 in Review

Y-Intercept (HK) sold out of Carisma Therapeutics (CARM) in Q3 2024, closing a stake of 75,501 shares — an estimated $115K sold.

Y-Intercept (HK) first reported a position in CARM in Q2 2022 and held it in 2 quarters. The position peaked at $115K in Q2 2024. 37 funds tracked by Wall St. Rank hold CARM as of Q3 2024.

  • Y-Intercept (HK) reported no remaining Carisma Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Y-Intercept (HK) sold 75,501 Carisma Therapeutics shares in Q3 2024, an estimated $115K.
  • Y-Intercept (HK) first reported a position in Carisma Therapeutics in Q2 2022 and held it in 2 quarters.
  • Y-Intercept (HK)'s Carisma Therapeutics position peaked at $115K in Q2 2024.
  • 37 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q3 2024.

Based on Y-Intercept (HK)'s 13F filing for Q3 2024, filed 15 Nov 2024.